蒽环类抗生素致心脏毒性的研究进展  

Research Progress of Anthracycline Antibiotics Induced Cardiotoxicity

作　　者：凌亚豪 郑敏 靳洪涛[3,4] Ling Ya-hao;Zheng Min;Jin Hong-tao(Institute of Laboratory Animal Sciences',Chinese Academy of Medical Sciences & Comparative Medicine Center, Peking Union Medical College,Beijing 100021;Dalang Community Health Center of the people's Hospital in Longhua District,Shenzhen 518109;New Drug Safety Evaluation Center,Institute of Materia Medica,Chinese Academy of Medical Sciences & Peking Union Medical College,Beijing 100050;Beijing Union-Genius Pharmaceutical Technology Development Co.,Ltd.,Beijing 100176)

机构地区：[1]中国医学科学院医学实验动物研究所北京协和医学院比较医学中心,北京100021 [2]龙华区人民医院大浪社康中心,深圳518109 [3]中国医学科学院药物研究所新药安全评价研究中心,北京100050 [4]北京协和建昊医药技术开发有限责任公司,北京100176

出　　处：《国外医药（抗生素分册）》2019年第1期20-24,共5页World Notes on Antibiotics

摘　　要：蒽环类抗生素目前广泛地用于治疗血液系统恶性肿瘤和实体肿瘤,但其容易产生严重的心脏毒性作用。关于蒽环类抗生素相关心脏毒性发病机制尚未完全阐明。本文对近年来蒽环类抗生素致心脏毒性的机制进行综述,为有效的临床防治和蒽环类抗生素研发提供参考。Anthracycline antibiotics,chemotherapeutic agents that have long been used to treating hematologic and solid tumors,currently are prone to make severe cardiotoxicity.The pathogenesis of cardiotoxicity associated with anthracycline antibiotics has not been completely clarified.This paper reviewed the progress in the pathogenesis of cardiotoxicity associated with anthracycline antibiotics in recent years,providing a reference for the effective clinical treatment and useful information for further research on anthracycline antibiotics.

关 键 词：蒽环类抗生素 心脏毒性 发病机制 

分 类 号：R595.3[医药卫生—内科学]